• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Chimerix, Inc. - Common Stock (NQ: CMRX )

    3.340 UNCHANGED
    Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Chimerix, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings
    Via Benzinga
    Dow Falls 150 Points; Oracle Posts Downbeat Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
    Chimerix plans to submit an NDA for dordaviprone to treat H3 K27M-mutant glioma, with potential U.S. FDA approval targeted for late 2025. 
    Via Benzinga
    Exposures Product Safety
    CMRX Stock Earnings: Chimerix Misses EPS for Q1 2024
    CMRX stock results show that Chimerix missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Earnings Scheduled For February 29, 2024
    Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
    Via Benzinga
    Preview: Chimerix's Earnings
    Via Benzinga
    Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    CMRX Stock Earnings: Chimerix Meets EPS, Beats Revenue for Q2 2024
    CMRX stock results show that Chimerix met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
    EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures COVID-19
    Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
    From FN Media Group LLC
    Via GlobeNewswire
    Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Appoints Marc D. Kozin to Board of Directors
    Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience 
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Present at TD Cowen 44th Annual Health Care Conference
    From Chimerix, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.